0.7887
price up icon1.83%   0.0142
after-market 시간 외 거래: .79 0.0013 +0.16%
loading
전일 마감가:
$0.7745
열려 있는:
$0.7736
하루 거래량:
145.16K
Relative Volume:
0.63
시가총액:
$26.34M
수익:
-
순이익/손실:
$-10.21M
주가수익비율:
-1.3501
EPS:
-0.5842
순현금흐름:
-
1주 성능:
-7.21%
1개월 성능:
-10.42%
6개월 성능:
-35.35%
1년 성능:
-26.35%
1일 변동 폭
Value
$0.75
$0.7899
1주일 범위
Value
$0.75
$1.05
52주 변동 폭
Value
$0.6801
$2.60

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name
명칭
Neurosense Therapeutics Ltd
Name
전화
-
Name
주소
-
Name
직원
15
Name
트위터
Name
다음 수익 날짜
2026-04-06
Name
최신 SEC 제출 서류
Name
NRSN's Discussions on Twitter

Compare NRSN vs VRTX, REGN, ARGX, ALNY, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NRSN
Neurosense Therapeutics Ltd
0.7887 25.87M 0 -10.21M 0 -0.5842
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.05 114.72B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
737.45 78.67B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
684.50 42.38B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
311.10 41.75B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
282.72 31.33B 5.36B 287.73M 924.18M 2.5229

Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스

pulisher
Mar 18, 2026

NeuroSense (NRSN) director Pellizzari details option and share holdings - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

NeuroSense Therapeutics (NRSN) CMO details option and warrant holdings - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

NeuroSense (NRSN) director details options and restricted share holdings - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

NeuroSense (NRSN) GM Hagit Binder details share, option and RSU holdings - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

/C O R R E C T I O N -- NeuroSense/ - PR Newswire

Mar 18, 2026
pulisher
Mar 18, 2026

Bull Bear: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingStop Loss & AI Enhanced Market Trend Forecasts - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 18, 2026

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail

Mar 18, 2026
pulisher
Mar 18, 2026

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference - PR Newswire

Mar 18, 2026
pulisher
Mar 18, 2026

Neurosense Therapeutics Ltd - Reuters

Mar 18, 2026
pulisher
Mar 18, 2026

NeuroSense Therapeutics (NRSNW) Projected to Post Quarterly Earnings on Wednesday - Defense World

Mar 18, 2026
pulisher
Mar 18, 2026

Director at NeuroSense (NASDAQ: NRSN) discloses equity awards and vesting - Stock Titan

Mar 18, 2026
pulisher
Mar 17, 2026

EPS Watch: Whats the fair value of NeuroSense Therapeutics Ltd stock2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 17, 2026

Is United Therapeutics Corporation gaining market share2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 17, 2026

Aug Opening: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2026 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 17, 2026

Breakout Watch: Will NeuroSense Therapeutics Ltd Equity Warrant benefit from green energy policiesTrend Reversal & Consistent Return Investment Signals - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 16, 2026

FOMO Trade: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2026 Top Gainers & Free Safe Entry Trade Signal Reports - baoquankhu1.vn

Mar 16, 2026
pulisher
Mar 16, 2026

Published on: 2026-03-17 06:01:38 - baoquankhu1.vn

Mar 16, 2026
pulisher
Mar 16, 2026

NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology - TipRanks

Mar 16, 2026
pulisher
Mar 16, 2026

[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - PR Newswire

Mar 16, 2026
pulisher
Mar 15, 2026

Tangible book value per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView

Mar 15, 2026
pulisher
Mar 13, 2026

Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50 - Defense World

Mar 13, 2026
pulisher
Mar 13, 2026

Operating cash flow per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView

Mar 13, 2026
pulisher
Mar 12, 2026

NeuroSense Shareholders Approve Increase in Registered Share Capital - The Globe and Mail

Mar 12, 2026
pulisher
Mar 10, 2026

NeuroSense "PrimeC" Market size expansion of Several Folds by 2034 - openPR.com

Mar 10, 2026
pulisher
Mar 10, 2026

This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Mar 10, 2026
pulisher
Mar 10, 2026

Roth/MKM initiates NeuroSense stock with buy on ALS drug potential - Investing.com Nigeria

Mar 10, 2026
pulisher
Mar 10, 2026

Roth/MKM initiates NeuroSense stock with buy on ALS drug potential By Investing.com - Investing.com South Africa

Mar 10, 2026
pulisher
Mar 09, 2026

Neurosense Therapeutics Ltd. Presents Long-Term Survival Data for Primec in Amyotrophic Lateral Sclerosis - marketscreener.com

Mar 09, 2026
pulisher
Mar 09, 2026

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - PR Newswire

Mar 09, 2026
pulisher
Mar 08, 2026

Analysis Recap: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leadersMarket Sentiment Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Mar 08, 2026
pulisher
Mar 07, 2026

Long-Term Data From PARADIGM Trial Suggest Survival Benefit With PrimeC in ALS - NeurologyLive

Mar 07, 2026
pulisher
Mar 07, 2026

Buy Signal: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectationsSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 07, 2026

Will NeuroSense Therapeutics Ltd. stock continue upward momentumJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - Naître et grandir

Mar 07, 2026
pulisher
Mar 06, 2026

Insider Sell: What are the risks of holding NeuroSense Therapeutics Ltd Equity WarrantJuly 2025 Update & Capital Efficiency Focused Ideas - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

Revenue Check: Whats the fair value of NeuroSense Therapeutics Ltd stockRisk Management & Fast Exit and Entry Trade Guides - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

Published on: 2026-03-06 17:33:43 - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 04, 2026

NRSN SEC FilingsNeurosense Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Revenue Check: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2025 Technical Patterns & Verified Momentum Stock Ideas - baoquankhu1.vn

Mar 04, 2026
pulisher
Mar 01, 2026

IANS - IANS

Mar 01, 2026
pulisher
Feb 28, 2026

Book value per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView

Feb 28, 2026
pulisher
Feb 28, 2026

Buyback Watch: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right now2025 Market WrapUp & Verified Momentum Watchlists - baoquankhu1.vn

Feb 28, 2026
pulisher
Feb 25, 2026

NRSN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 25, 2026
pulisher
Feb 23, 2026

Panic Selling: Is NeuroSense Therapeutics Ltd still a buy after recent gains2025 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn

Feb 23, 2026
pulisher
Feb 22, 2026

Activity Recap: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowJuly 2025 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn

Feb 22, 2026
pulisher
Feb 21, 2026

Earnings Miss: What is VCICs valuation compared to sector2025 Momentum Check & Real-Time Price Movement Reports - baoquankhu1.vn

Feb 21, 2026
pulisher
Feb 21, 2026

Gap Down: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesTrade Exit Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn

Feb 21, 2026
pulisher
Feb 20, 2026

Why is NeuroSense Therapeutics Ltd. stock going downMarket Volume Summary & Daily Risk Controlled Trade Plans - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

What are NeuroSense Therapeutics Ltd. Equity Warrant’s recent SEC filings showingStop Loss & Weekly High Conviction Ideas - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

ALS drug PrimeC cuts death risk by 65% - Longevity.Technology

Feb 20, 2026
pulisher
Feb 20, 2026

Is NeuroSense Therapeutics Ltd. Equity Warrant stock safe for conservative investorsPortfolio Value Report & Long-Term Safe Investment Ideas - mfd.ru

Feb 20, 2026

Neurosense Therapeutics Ltd (NRSN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$99.29
price up icon 1.20%
$27.80
price up icon 0.00%
$52.37
price down icon 0.06%
$89.31
price down icon 0.77%
$144.00
price up icon 0.91%
biotechnology ONC
$282.72
price up icon 0.15%
자본화:     |  볼륨(24시간):